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m.3291TNC mutation in the MT-TL1 gene has been infrequently encountered in association with mitochondrial
myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS), however remains poorly character-
ized from a clinical perspective. In the following report we describe in detail the phenotypic features, long term
follow up (N7 years) and management in a Caucasian family with MELAS due to the m.3291TNC mutation and
review the literature onm.3291TNCmutation. The clinical phenotype in the proposita included overlapping fea-
tures of MELAS, MERRF (Myoclonic epilepsy and ragged-red fiber syndrome), MNGIE (Mitochondrial
neurogastrointestinal encephalopathy), KSS (Kearns-Sayre Syndrome) and CPEO (Chronic progressive external
ophthalmoplegia).









MELAS (MIM #540000), most commonly involves an adenine-to-
guanine transition mutation at position 3243 of the mitochondrial
genome (m.3243ANG) [1]. This mutation involves the MT-TLI gene
that encodes for a mitochondrial tRNAleu (UUR) [2]. As is true of
many of the mitochondrial encephalopathies, there remains a lack
of a distinctive genotype-phenotype relationship in MELAS due to
heteroplasmy. A rare mitochondrial mutation, m.3291TNC was first
identified to be associated with the MELAS phenotype by Goto et al.
[3]. Located in the tRNALeu (UUR), the mutation was described in a
Japanese boy with a classic MELAS phenotype [3]. Subsequent re-
ports, however, have identified this mitochondrial mutation in asso-
ciation with a number of different phenotypic presentations (see
Table 1). Here, we describe a familial case of a m.3291TNCmitochon-
drial mutation with MELAS and additional manifestations that have
not been previously well characterized.
2. Case report
A 15 year old Caucasian girl of Dutch ancestry was admitted to the
pediatric critical care unit for themanagement of herfirst episode of sta-
tus epilepticus. She was the first child of non-consanguineous parents
(Fig. 1). Pregnancy and delivery were uneventful and early develop-
ment was reportedly normal.
Despite control of seizure activity, during the recovery phase, the pa-
tient continued to need ventilation support, and after extubation,
remained confused with inconsistent responses, fluctuating awareness
and an encephalopathic state. Investigative work up for infectious
causes was normal and a urine toxicology screenwas found to be nega-
tive at admission. Further, on reviewing the history, long standing
symptoms of easy fatigability, generalized weakness were noted. Her
weight was 35.7 kg (b3rd centile) and height was 173 cm (75th
centile). Neurological examination during recovery disclosed addi-
tional clinical findings that included; bilateral ptosis, significant lim-
itation of extra ocular movements (external ophthalmoplegia) (this
had been previously missed) (Fig. 2), eyelid myoclonia and distal
polymyoclonus in the hands. During the recovery phase and subse-
quent follow up over the course of a year, recurrent stroke -like epi-
sodes, signs of gastroparesis, poor gut motility manifesting with
constipation became evident.
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Table 1
Clinical phenotypes reported with m.3291TNC mutation.
Age
(yrs)
Gender Clinical features Lactate level
(0.5–2.2 mmol/L)
Other laboratory investigations Molecular
investigations
Mitochondrial syndrome Reference





EEG Multiple spike and wave complexes
CT scan bilateral symmetric calcification
in basal ganglia
RRF in muscle
m.3291TNC 93% in muscle MELAS/
MERRF
[13]








MRI atrophy or frontal lobe and
cerebellar cortex
RRF in muscle
m.3291TNC 16-27% in blood
amongst various family members
Mitochondrial encephalo-myopathy [12]






EEG slow wave dysrhythmia
RRF in muscle
m.3291TNC 86% in muscle
30% in whole blood
MELAS [3]




2046 μmol/L (500–1800) MRI
Diffuse supratentorial and infratentorial
atrophy
EEG slow wave dysrhythmia
EKG WPW syndrome
RRF in muscle
m.3291TNC 95% in muscle Non-syndromic mitochondrial disorder [11]
7.6 F Mild myopathy (4238 mM,
b1800)
MRI
Diffuse supratentorial and infratentorial
atrophy
EEG slow wave dysrhythmia
EKG WPW syndrome
RRF in muscle
m.3291TNC 87% in muscle Mild myopathy disorder [10]
48 M Complex phenotype of myoclonus epilepsy with
ragged-red fibers (MERRF) syndrome and
Kearns-Sayre syndrome (KSS): progressive
myoclonus epilepsy, cerebellar ataxia, hearing loss,
myopathic weakness, ophthalmo-paresis,
pigmentary retinopathy, bifascicular heart block
24.1 mg/dL (normal b22) Muscle biopsy demonstrated markedly
increased RRF
















The proposita's mother was 36 years old at diagnosis and has suffered
frommigraine headaches. Therewas also a history ofmigraine headaches
in the maternal grandmother and a maternal great aunt. The proposita's
siblings, an 18 year old brother has recently developed some fatigue
and a 16 year old sister has presentedwith headaches but overall the sib-
lings are relatively asymptomatic. The lactate levels are normal for all the
three maternal relatives. The EKG and cardiac evaluation is normal in the
mother. The mother is also on the mitochondrial cocktail including ribo-
flavin 400 mg once a day, Carnitor 330 mg 1 tablet 3 times a day, alpha-
lipoic acid 100 mg 3 capsules twice daily, CoQ 100 mg 2 capsules 3
times daily, L-arginine 100 mg/mL 60 mL 3 times a day.
2.1. Biochemical & Pathology investigations
Laboratory tests demonstrated a persistent elevation in blood
lactate levels 4–7 (normal 0.5–2.2 mmol/L) in the proposita. EEG
(Electroencephalogram) confirmed the presence of diffusely slow back-
ground rhythmswith no epileptiform activity consistent with a moder-
ately severe encephalopathy. Brain magnetic resonance imaging (MRI)
showed multifocal ill-defined hyperintense lesions in the grey and
white matter of the temporal lobes and orbito-frontal regions (Fig. 3).
There was an inverted lactate peak on brain magnetic resonance
spectroscopy (MRS) (Fig. 4). A muscle biopsy was performed in the
proposita on the left thigh. Histopathology of the stainedmuscle biopsy
of the left thigh showed numerous scattered ragged red fibers which
were highlighted by the modified Gomori trichome stain. There were
numerous ragged blue fibers positive for succinate dehydrogenase reac-
tion. Many fibers were devoid of cytochrome c oxidase (COX). Electron
microscopy revealed increased subsarcolemmal accumulation of mito-
chondria. These mitochondria showed marked variation in size and
shape with abnormal cristae architecture. The results of respiratory
chain enzyme assays on muscle homogenate were within reference
ranges but demonstrated a relatively reduced activity of complex
I + III (ratio to citrate synthase 0.041 (0.033–0.110)) in comparison
with other complexes. A diagnosis of a mitochondrial cytopathy, likely
MELAS was made.
2.2. Molecular diagnosis
DNA samples were prepared from the muscle biopsy and blood and
urine specimens from the proposita. Sanger sequencing after PCR am-
plification of tRNAleu (UUR) demonstrated a heteroplasmic m.3291TNC
mutation in the proposita. The percent heteroplasmy was calculated
using densitometry software (GelDoc-Bio-Rad Image analyzer) after
Fig. 1. Showing Pedigree with multiple affected individuals.
Fig. 2. Proposita with bilateral ptosis.
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polyacrylamide gel electrophoresis of restriction enzyme (TSP509I New
England Biolabs, Whitby, Ontario, Canada) fragments after PCR amplifi-
cation. The level of heteroplasmy varied with tissue sampled: muscle
biopsy contained 75% mutated mtDNA, urine 35%, blood 30%, and
cultured primary skin fibroblasts 25%. Negative results were obtained
with targeted mtDNA analysis for m.3243ANG, m.3260ANG,
m.3303CNT, m.8344ANG, m.8993TNG/C and deletions.
The m.3291TNC mutation was also demonstrated in the blood of
proposita'smother, brother and sisterwith 11%, 14% and 5% lymphocyte
mutantmtDNA respectively. Urine DNA and other tissueswere not test-
ed for the proposita's mother, brother and sister.
The patient is currently in a stable clinical condition and is main-
tained on amitochondrial cocktail and anticonvulsants including; Coen-
zymeQ120mg TID, vitamin C 500mgBID, Thiamin 100mgOD, Vitamin
E 400 IU BID, Creatine 2.5 g BID, lamotrigine 175 mg BID, topiramate
25 mg AM and 50 mg HS and oral L-Arginine (0.15 g/kg) TID.
2.3. Follow up evaluations
The patient is presently 22 years old and continues to demonstrate
ptosis, external ophthalmoplegia, easy fatigability and occasional head-
aches. Further she has also been diagnosedwithWolff-Parkinson-White
syndrome (WPW) on the basis of EKGfindings, but remains asymptom-
atic from a cardiac point of view. She has not had any further hospitali-
zations since the introduction of arginine to her mitochondrial cocktail.
Prior to this she was having at least 2–3 hospitalizations per year.
Initial neuropsychological assessment (15 years of age) was limited
due to fatigue, poor attention, distractibility, poor comprehension of
task demands, and significant anxiety. She demonstrated weak compre-
hension of vocabulary (7th percentile) and impaired comprehension of
spoken instructions (b1st percentile) and expressive language (1st–3rd
percentiles). Verbal immediate and working memory, and estimates of
verbal intellectual and performance (non-verbal) reasoning skills were
within the extremely low range (≤1st percentile). Performance on a test
of verbal learning was average (25th percentile). Although reported to
have an academic average over 75% in Grade 9, tests of academic achieve-
ment were well below age expectations (b1st–3rd percentiles). Subse-
quent assessments carried out at 16 and 17 years of age document
improvements in her verbal intellectual skills (10th percentile), under-
standing of language (13th–30th percentiles), and verbal memory
(25th–84th percentile). Impairments in perceptual reasoning (1st per-
centile),workingmemory (1st percentile), visualmemory (5th–16thper-
centile), and processing speed (1st percentile) persist with significant
difficulty noted in aspects of executive functioning such as cognitive flex-
ibility in day-to-day activities and concept formation (9th percentile).
Performance on tests of academic achievement improved but continued
to range from just below average to low (3rd–13th percentiles). Current-
ly, she requires guidance and supervision to complete activities of daily
living. Due to ongoing fatigue, she completed high school at the pace of
one or two subjects at home or in school. She has received counseling in
her community for anxiety and helping her cope with the many medical
issues and social implications of her diagnosis.
3. Discussion
The m.3291TNC mutation is in the TψC loop of tRNALeu(UUR). The
pathogenicity of m.3291TNC has been assessed by several criteria. It is
Fig. 3. Axial FLAIR (Fluid Attenuation Inversion Recovery, figure A) sequence shows multiple areas of brain parenchymal high signal (long white arrow) in the temporal lobes bilaterally
and the right occipital lobe. FLAIR image 4 years later (figure B) reveals an old infarct in the right temporal lobe (white arrowheads) but the other areas of signal abnormalities have
returned to normal.
Fig. 4. Single voxel MR spectroscopy (TE144) obtained at the same time as figure A
showed the characteristic inverted doublet of lactate within one of the areas of
abnormality.
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identified in theMitomapmutations database as causing disease [4]. It is
a rare variant that is not present in the Mitomap polymorphism data-
base that is derived from 30,589 panethnic GenBank sequences or the
2704 sequences in the mtDB-Human Mitochondrial Genome Database
[5]. m.3291TNC is not highly conserved and 4 (Cercopithecus aethiops,
Hylobates lar, Macaca sylvanus, Papio hamadryas) of 16 primate tRNA-
Leu(UUR) with 7 nucleotide long TψC loop is listed in theMamit-tRNA da-
tabase [6]. m.3291TNC is replaced by cytosine seemingly without being
deleterious. Ding and Leng (2012) questioned the pathogenicity of
m.3291TNC mutation on the basis of both the lack of sequence conser-
vation and the predicted secondary structural similarity based on the
small change of minimal free energy created by the CNT transition [7].
Kirino et al. [8] demonstrated that the functional impact of the
m.3291TNC mutation was to reduce the percentage of the 5-
taurinomethyluridine (τm5U) modification at the anticodon wobble
position of the tRNA Leu(UUR) presumably affecting the accuracy or effi-
ciency of translation in common with other MELAS causing mutations.
The question of pathogenicity seems to have been resolved by Yarham
et al by identifying that them.3291TNC transition segregatedwith cyto-
chrome oxidase deficiency in single muscle fibers in a biopsy from a pa-
tient who presented with deafness and lipomas [9].
Further support for pathogenicity is the variable heteroplasmy in
blood (30%), cultured primary fibroblasts (25%) and muscle biopsy
(75%) seen in the patient described herein, the maternal inheritance
in this family, the varying level of heteroplasmy and symptoms in the
patient's mother and two siblings.
Themutationm.3291TNCwas reported in an Italian girl with an iso-
lated myopathy [10], and a young Italian woman with progressive cog-
nitive and behavioral decline with hearing loss [11]. The authors have
named this as non-syndromic mitochondrial disorder. Sunami et al
described a case of an elderly Japanese woman with the m.3291TNC
mutationwhopresentedwithmild ophthalmoparesis alongwith severe
cerebellar ataxia,mild proximalmyopathy, hearing loss and diffuse par-
oxysmal slow activity on EEG. Therewas no lactic acidosis. Clinicalman-
ifestations and muscle biopsy suggested MERRF with a family history
positive for numerous symptoms suggestive of amitochondrial enceph-
alopathy [12].
The proposita's clinical presentation, including seizures, stroke-like
episodes, recurrent headaches and progressive cognitive decline, along
with persistent lactic acidosis and findings on muscle biopsy, WPW
syndrome, cranial MRI and MRS are all consistent with the diagnosis
ofmitochondrial pathology. Based on both clinical and histological find-
ings, initially the proposita's phenotype was deemed consistent with
MERRF or CPEO. A similar MERRF/MELAS overlap syndrome due to the
m.3291TNC was reported in Chinese teenager [13].
The presence of external ophthalmoplegia is not a common feature
of MELAS m.3291TNC and is considered to be typical for KSS or CPEO.
One of the recent reports have shown that the m.3291TNC mutation
was also described in a man with a MERRF and KSS [14]. Unlike KSS,
there was no evidence of ataxia or retinitis pigmentosa in our patient.
Our patient did have evidence of cardiac conduction disturbance on
EKG showing WPW syndrome; however KSS typically includes
prolonged intraventricular conduction time, bundle branch blocks and
complete AV block.
Our case is of interest as her presentation is of an overlap syndrome
including features of MELAS/MERRF, KSS or CPEO and alsoMNGIE, poor
nutrition and some gastroparesis in association with the m.3291TNC
mutation (Fig. 5).
mtDNA mutations demonstrate a large phenotypic variability in
their presentation. Similar tom.3243ANGmutation, phenotypes associ-
ated with the m.3291TNC mutation are variable. The proposita has
responded well to nutrition support and oral arginine [15]. Her current
weight is 51 kg. Over the last few years after introduction of oral argi-
nine she has not had any further episodes of status epilepticus or
strokes. However more research needs to be conducted on arginine
use [15].
4. Conclusions
This family extends the phenotype of m.3291TNC mutation to in-
clude features of status epilepticus, CPEO/KSS, MNGIE, MERRF and
MELAS in the proposita. Based on the above case and the review of liter-
aturewe propose that them.3291TNC is a pathogenicmutation. Clinical
phenotype will depend on the level of heteroplasmy. Patients with the
rarem.3291TNCmutation causingMELASmay also benefit with the ad-




MELAS mitochondrial myopathy encephalopathy lactic acidosis and
stroke-like episodes
MERRF myoclonic epilepsy and ragged-red fiber syndrome
MNGIE mitochondrial neurogastrointestinal encephalopathy
tRNA transfer RNA
CPEO chronic progressive external ophthalmoplegia
KSS Kearns–Sayre Syndrome
Fig. 5. Overlapping Mitochondrial syndromes. (The patient described in the report has many of the features of the clinical phenotypes encountered in MERFF, CPEO, KSS, MELAS, and
MNGIE).
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RRF ragged-red fiber
WPW Wolff–Parkinson–White syndrome
AV block atrioventricular block
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